Collagen sponges for bone regeneration with rhBMP-2

被引:616
作者
Geiger, M
Li, RH
Friess, W
机构
[1] Wyeth BioPharma, Drug Prod Dev, Andover, MA 01810 USA
[2] Wyeth Ayerst Res, Cambridge, MA 02140 USA
[3] Univ Munich, Dept Pharm, Lehrstuhl Pharmazeut Technol & Biopharm, D-81377 Munich, Germany
关键词
bone regeneration; osteoconduction; osteoinduction; rhBMP-2; differentiation factors; tissue engineering; collagen; formaldehyde cross-linking; ethylene oxide sterilization; dehydrothermal treatment;
D O I
10.1016/j.addr.2003.08.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the US alone, approximately 500,000 patients annually undergo surgical procedures to treat bone fractures, alleviate severe back pain through spinal fusion procedures, or promote healing of non-unions. Many of these procedures involve the use of bone graft substitutes. An alternative to bone grafts are the bone morphogenetic proteins (BMPs), which have been shown to induce bone formation. For optimal effect, BMPs must be combined with an adequate matrix, which serves to prolong the residence time of the protein and, in some instances, as support for the invading osteoprogenitor cells. Several factors involved in the preparation of adequate matrices, specifically collagen sponges, were investigated in order to test the performance in a new role as an implant providing local delivery of an osteoinductive differentiation factor. Another focus of this review is the current system consisting of a combination of recombinant human BMP-2 (rhBMP-2) and an absorbable collagen sponge (ACS). The efficacy and safety of the combination has been clearly proven in both animal and human trials. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:1613 / 1629
页数:17
相关论文
共 112 条
[31]  
EMEA, 2000, CPMPQWP05498 EMEA
[32]  
*EMEA, 2002, CPMP318802 EMEA
[33]  
*EMEA, 2001, CPMPQWP15901 EMEA
[34]   Collagen - biomaterial for drug delivery [J].
Friess, W .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 45 (02) :113-136
[35]   Basic thermoanalytical studies of insoluble collagen matrices [J].
Friess, W ;
Lee, G .
BIOMATERIALS, 1996, 17 (23) :2289-2294
[36]   Characterization of absorbable collagen sponges as rhBMP-2 carriers [J].
Friess, W ;
Uludag, H ;
Foskett, S ;
Biron, R ;
Sargeant, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 187 (01) :91-99
[37]   Bone regeneration with recombinant human bone morphogenetic protein-2 (rhBMP-2) using absorbable collagen sponges (ACS): Influence of processing on ACS characteristics and formulation [J].
Friess, W ;
Uludag, H ;
Foskett, S ;
Biron, R .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 1999, 4 (03) :387-396
[38]  
Friess W, 2000, DRUG DELIVERY SYSTEM, P94
[39]  
GEIGER M, 2000, P 3 WORLD M APV APGE, P239
[40]  
GEIGER M, 2001, THESIS U ERLANGEN NU